American Society of Nephrology guidance on cardiovascular-kidney-metabolic syndrome in kidney disease: tracking eGFR and albuminuria, using PREVENT and KFRE risk equations, and sequential or combined SGLT2 inhibitor, GLP-1, nonsteroidal MRA, RAS and lipid therapy.
Guideline
Bansal et al. ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome